
Press Release - For Immediate Release

AsiaMedic Makes New Board Appointments

Singapore, 13 June 2012 – SGX Catalist-listed AsiaMedic Limited (“AsiaMedic”, “亚美德科医疗集团”, or the “Group”), a growing premier healthcare provider in Asia, has announced the appointment of Mr. Tan Wang Cheow as Non-Executive Chairman and Director, and Mr. Mark Erhart as Non-Executive Independent Director with effect from 13 June 2012.

Mr. Tan is currently Chairman and Managing Director of SGX mainboard-listed Food Empire Holdings Limited (“Food Empire”). As a founder of Food Empire, Mr. Tan took the company public in 2000. Over the years, he has been instrumental in guiding Food Empire towards achieving its long-term goals. Besides overseeing the day-to-day operations, Mr. Tan is responsible for formulating the company’s strategies in new business and market development as well as product innovation. He is also actively involved in its marketing and branding activities.

Mr. Erhart is the founder and Managing Director of healthcare-focused investment advisory and consulting firm Sentosa Capital Advisors Pte Ltd. Mr. Erhart joins the Board with a track record of significant value creation for shareholders and investors as well as board director experience at eight companies. He has extensive direct investment and deal experience of the healthcare sector in Europe, Asia and the Middle East. Prior to setting up Sentosa Capital Advisors, Mr. Erhart was the Executive Director, Healthcare at Mubadala Development Company from 2006 to 2010; and the Vice President, Corporate Development at Parkway Group Healthcare Pte Ltd from 2002 to 2006.

Commenting on the new appointments, Mr. Andi Solaiman, Non-Executive Director of AsiaMedic, said: *“On behalf of the Board of Directors and management team, we are pleased to welcome Mr. Tan and Mr. Erhart to our board. Both men are very well-qualified in their respective fields in terms of proven track records and professional management expertise.*

With Mr. Erhart’s appointment, AsiaMedic’s board comprises three independent directors who make up half of the board, and this demonstrates the Group’s commitment to a diverse and effective board composition.

We look forward to the contributions of Mr. Tan and Mr. Erhart; and believe their insights and experience will benefit the Group and our shareholders well.”

- END -

This document is to be read in conjunction with AsiaMedic Limited's exchange filings on 13 June 2012, which can be downloaded via www.sgx.com.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Asiasons WFG Capital Pte Ltd (the "Sponsor"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.

Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Asiasons WFG Capital Pte Ltd)
Address: 70 Anson Road, #24-01 Hub Synergy Point, Singapore 079905
Telephone number: (65) 6319 4954

Media & Investor Contacts

| | |
|---|---|
| Mr. Seah Han | Mr. Andy Lin |
| Direct Line: +65 6517 8780 | Direct Line: +65 6517 8775 |
| Mobile: +65 8318 1820 | Mobile: +65 9651 7743 |
| Email: han.seah@shareinvestor.com | Email: andy.lin@shareinvestor.com |

About AsiaMedic (Bloomberg: AMAT:SP / Reuters: ASIM.SI)

Headquartered in Singapore and listed on the Catalist Board of the Singapore Stock Exchange, AsiaMedic Limited is a premier healthcare provider that focuses on the management of clinical services in the fields of disease prevention, early illness detection and advanced diagnostics. Its team of highly qualified and reputable professionals provides clinical and management services both in Singapore and overseas.

The services provided by AsiaMedic include but are not limited to health-risk assessments and screening, general and subspecialty imaging such as MRI and CT Scans for cardiovascular, neuroradiological, ENT and musculoskeletal imaging; PET/CT imaging for diagnosis, staging, localisation and monitoring progress of cancer.

Driven by its commitment to the core values of competence, care, convenience and collaboration, AsiaMedic has built up a strong brand name for delivering positive patient outcomes and high-quality care for its patients from Singapore and around the region.

Apart from Singapore, AsiaMedic has a growing presence in key growth markets such as China, Indonesia, Vietnam and Russia. Recognising the increasing demand for quality healthcare services in Asia and the Middle East, AsiaMedic expanded into the provision of international healthcare consultancy and management services in 2009.

As an endorsement of its strengths and track record in the regional healthcare services industry, AsiaMedic was awarded two high-profiled turnkey projects in Abu Dhabi by Mubadala Healthcare, a division of Mubadala Development Co. and owned by the Government of the Emirate of Abu Dhabi. The projects were successfully completed and handed over in early 2012.

Having tested and proven its healthcare services business model in Singapore and the region, AsiaMedic is developing more innovative healthcare services in selected markets for its next stage of growth.